Effect of ulinastatin donor-pretreatment on liver graft during cold preservation in rats

Chinese Medical Journal

Volumn 124, Issue 4, 2011, Pages 574-580

  Mao, Jie ^a   Zhang, Lin ^a   Song, Ai Lin ^a   Chen, Xiao ^a   Zhang, You Cheng ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Cold preservation injury; Donor pretreatment; Liver graft; Ulinastatin

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASE; LACTIC ACID; MALONALDEHYDE; SODIUM CHLORIDE; ULINASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DONOR; DRY WEIGHT; ENZYME ACTIVITY; FEMALE; GLYCOLYSIS; GRAFT PRESERVATION; LIVER GRAFT; LIVER INJURY; LIVER PROTECTION; LIVER WEIGHT; MALE; NONHUMAN; RAT;

ANIMALS; CALCIUM-TRANSPORTING ATPASES; CRYOPRESERVATION; GLYCOPROTEINS; GRAFT SURVIVAL; L-LACTATE DEHYDROGENASE; LIVER; LIVER TRANSPLANTATION; MALONDIALDEHYDE; ORGAN PRESERVATION; RATS; RATS, WISTAR; SODIUM-POTASSIUM-EXCHANGING ATPASE; TISSUE DONORS;

EID: 79951784510     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.04.017     Document Type: Article

References (42)

1. Sun Z, Klein AS, Radaeva S, Hong F, El-Assal O, Pan HN, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003; 125: 202-215.
2. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20 (4 Pt 1): 829-838.
3. Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Wahlstrom HE, Moore SB, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 2005; 16: 49-53.
4. Kadmon M, Bleyl J, Küppers B, Otto G, Herfarth C. Biliary complications after prolonged University of Wisconsin preservation of liver allografts. Transplant Proc 1993; 25 (1 Pt 2): 1651-1652.
5. Popescu I, Sheiner P, Mor E, Forman W, Borcich A, Emre S, et al. Biliary complications in 400 cases of liver transplantation. Mt Sinai J Med 1994; 61: 57-62.
6. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 1992; 53: 957-978.
7. Edwards EB, Roberts JP, McBride MA, Schulak JA, Hunsicker LG. The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. N Engl J Med 1999; 341: 2049-2053.
8. Krishnan H, Hannon MF, Bawa SM, Talbot D, Mirza D, Manas D, et al. Comparison of the efficacy of University of Wisconsin solution and Newcastle organ perfusion fluid in the preservation of livers for transplantation. Transpl Int 1998; 11 suppl 1: S387-S389.
9. Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. JAMA 1989; 261: 711-714.
10. Stratta RJ, Wood RP, Langnas AN, Duckworth RM, Markin RS, Marujo W, et al. The impact of extended preservation on clinical liver transplantation. Transplantation 1990; 50: 438-443.
11. Jaeschke H. Molecular mechanisms of hepatic ischemiareperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284: G15-G26.
12. Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125: 917-936.
13. Rentsch M, Kienle K, Mueller T, Vogel M, Jauch KW, Püllmann K, et al. Adenoviral bcl-2 transfer improves survival and early graft function after ischemia and reperfusion in rat liver transplantation. Transplantation 2005; 80: 1461-1467.
14. Kaizu T, Ikeda A, Nakao A, Takahashi Y, Tsung A, Kohmoto J, et al. Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival. Hepatology 2006; 43: 464-473.
15. Kienle K, Rentsch M, Müller T, Engelhard N, Vogel M, Jauch KW, et al. Expression of BCL-2 in liver grafts after adenoviral transfer improves survival following prolonged ischemia and reperfusion in rat liver transplantation. Transplant Proc 2005; 37: 439-441.
16. Strasberg SM, Lowell JA, Howard TK. Reducing the shortage of donor livers: what would it take to reliably split livers for transplantation into two adult recipients? Liver Transpl Surg 1999; 5: 437-450.
17. Sasaki K, Miyake H, Kinoshita T, Ikeyama S, Tashiro S. Protective effect of FK506 and thromboxane synthase inhibitor on ischemia-reperfusion injury in non-heart-beating donor in rat orthotopic liver transplantation. J Med Invest 2004; 51: 76-83.
18. Yu JB, Yao SL. Protective effects of hemin pretreatment combined with ulinastatin on septic shock in rats. Chin Med J 2008; 121: 49-55
19. Masuda T, Sato K, Noda C, Ikeda KM, Matsunaga A, Ogura MN, et al. Protective effect of urinary trypsin inhibitor on myocardial mitochondria during hemorrhagic shock and reperfusion. Crit Care Med 2003; 31: 1987-1992.
20. Inoue K, Takano H, Shimada A, Yanagisawa R, Sakurai M, Yoshino S, et al. Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol 2005; 67: 673-680.
21. Chen H, He MY, Li YM. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. Chin Med J 2009; 122: 883-888.
22. Okuhama Y, Shiraishi M, Higa T, Tomori H, Taira K, Mamadi T, et al. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999; 82: 34-42.
23. Hirose J, Ozawa T, Miura T, Isaji M, Nagao Y, Yamashiro K, et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 1998; 21: 651-656.
24. Aihara T, Shiraishi M, Hiroyasu S, Hatsuse K, Mochizuki H, Seki S, et al. Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-alpha in the liver. Transplant Proc 1998; 30: 3732-3734.
25. Okuhama Y, Shiraishi M, Higa T. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999; 82: 34-42.
26. Okuhama Y, Shiraishi M, Miyaguni T, Higa T, Tomori H, Hiroyasu S, et al. Evidence of neutrophil involvement in the protective effects of urinary trypsin inhibitor against ischemia reperfusion in vitro. Transplant Proc 1998; 30: 3723-3725.
27. Itabashi K, Ito Y, Takahashi T, Ishii K, Sato K, Kakita A. Protective effects of urinary trypsin inhibitor (UTI) on hepatic microvasculature in hypotensive brain-dead rats. Eur Surg Res 2002; 34: 330-338.
28. Itabashi K, Takahashi T, Ito Y, Ishii K, Sato K, Kakita A. Protective effects of urinary trypsin inhibitor on hepatic microvascular injury in hypotensive brain-dead rats. Transplant Proc 2003; 35: 114-116.
29. Kim YI, Chung HJ, Song KE, Hwang YJ, Lee JW, Lee YJ, et al. Evaluation of a protease inhibitor in the prevention of ischemia and reperfusion injury in hepatectomy under intermittent Pringle maneuver. Am J Surg 2006; 191: 72-76.
30. Kim YI, Hwang YJ, Song KE, Yun YK, Lee JW, Chun BY. Hepatocyte protection by a protease inhibitor against ischemia/reperfusion injury of human liver. J Am Coll Surg 2002; 195: 41-50.
31. Okida M, Masako O, Maruya H, Higashi T, Yukaya H. Intraoperative changes in blood coagulation and the effectiveness of ulinastatin during liver resection. J Anesth 1991; 5: 43-47.
32. Nobuoka T, Mizuguchi T, Oshima H, Shibata T, Kaji S, Nagayama M, et al. Impaired liver regeneration with humoral and genetic disturbances in urinary trypsin inhibitor-deficient mice. Liver Int 2009; 29: 979-987.
33. Furukawa K, Kamimura T, Mahune Y, Ohota H, Yoshida T, Ishihara N, et al. Two patients with severe alcoholic hepatitis accompanied by hypercytokinemia and granulocytic hyperelastasemia, successfully treated by intravenous infusion of urinastarine (Miraclid). J Gastroenterol Hepatol 2001; 16: 575-580.
34. Shimanuki K, Satake M. Evaluation of perioperative administration of methylprednisolone sodium succinate and urinary trypsin inhibitor for prevention of surgical stress. Fukushima J Med Sci 1999; 45: 93-107.
35. Smreková R, Vajdová K, Kukan M, Ulicná O, Lutterová M, Wsólová L, et al. A rapid, simple, and cost-effective method for screening liver preservation solutions in the rat. Transplantation 2000; 70: 430-436.
36. Hengstler JG, Utesch D, Steinberg P, Platt KL, Diener B, Ringel M, et al. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 2000; 32: 81-118.
37. Kim JD, Baker CJ, Danto SI, Starnes VA, Barr ML. Modulation of pulmonary NA+ pump gene expression during cold storage and reperfusion. Transplantation 2000; 70: 1016-1020.
38. Xiaoqiao Z, Rong M, Zhigang Y, Yong D, Xihong F, Jingzhong S. Protective effect of ulinastatin against ischemia-reperfusion injury in rat small bowel transplantation. Transplant Proc 2004; 36: 1564-1566.
39. Taie S, Yokono S, Ueki M, Ogli K. Effects of ulinastatin (urinary trypsin inhibitor) on ATP, intracellular pH, and intracellular sodium transients during ischemia and reperfusion in the rat kidney in vivo. J Anesth 2001; 15: 33-38.
40. Binns OA, DeLima NF, Buchanan SA, Mauney MC, Cope JT, Thies SD, et al. Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J Thorac Cardiovasc Surg 1996; 112: 607-613.
41. Gupta R, Verma I, Sharma S, Ganguly NK. Prevention of tissue injury in an ascending mouse model of chronic pyelonephritis--role of free radical scavengers. Comp Immunol Microbiol Infect Dis 2004; 27: 225-234.
42. Cai M, Ogawa R. Effects of free radical scavengers, methylprednisolone, and ulinastatin on acute xanthine and xanthine oxidase-induced lung injury in rats. Circ shock 1994; 43: 71-78.